drugset
drugset / Trial / NCT05387837

Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME

NCT05387837 ↗

Phase 2 Active not recruiting 50 enrolled Ashvattha Therapeutics, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME)

Timeline

Start
2022-08-31
Primary completion
2025-05-09
Completion
2025-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Migaldendranib Small molecule 0.18 mg/kg Subcutaneous
Subject Migaldendranib Small molecule 0.36 mg/kg Subcutaneous
Subject Migaldendranib Small molecule 0.71 mg/kg Subcutaneous
Subject Migaldendranib Small molecule 1.5 mg/kg Subcutaneous
Subject Migaldendranib Small molecule 2 mg/kg Subcutaneous

Indications

diabetic macular edema wet macular degeneration